Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH
Author:
Publisher
Elsevier BV
Reference58 articles.
1. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement;Eslam;J. Hepatol.,2020
2. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association;Chalasani;Am. J. Gastroenterol.,2012
3. Non-alcoholic fatty liver disease – a global public health perspective;Younossi;J. Hepatol.,2019
4. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer;Huang;Cell Metabol.,2022
5. Changing epidemiology, global trends and implications for outcomes of NAFLD;Wong;J. Hepatol.,2023
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors;European Journal of Medicinal Chemistry;2024-10
2. Potential safety implications of fatty acid-binding protein inhibition;Toxicology and Applied Pharmacology;2024-10
3. Tea Polyphenols Inhibit Methanogenesis and Improve Rumen Epithelial Transport in Dairy Cows;Animals;2024-09-04
4. CBFA2T3 Is PPARA Sensitive and Attenuates Fasting-Induced Lipid Accumulation in Mouse Liver;Cells;2024-05-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3